SOLV

SOLV Solventum Corporation

Stock · NYSE · United States · Healthcare · US83444M1018

NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Solventum Corporation, and has no access to any account you may have with it. The name and the logo belong to their owners.

Price 90.38 USD +3.67%

52-week range 62.38 – 94.16

Dividend yield—

Market cap15.4B

NowoTrade score 9 Grade A

Price history

Daily prices in USD.

Updated 08 Nov 2026 14:36. Information, not advice.

Results

Next results 25 Feb 2027 in 109 days · 16:00 · estimate 1.78

Last results 1.45 vs 1.34 estimated 05 Nov 2026 · Beat +7.9%

Beat the estimate 11 of 11 0 missed · 0 in line · 11 beats in a row

Average surprise +12.3% reported against the estimate, last 11 quarters

Earnings per share: estimate and reported

Estimate Reported: beat Reported: miss In line

Quarterly results

Date	EPS estimate	EPS reported	Surprise	Result
25 Feb 2027 16:00	1.78	—	—	Upcoming
05 Nov 2026 16:00	1.34	1.45	+7.9%	Beat
05 Aug 2026 16:00	1.91	2.55	+33.8%	Beat
05 May 2026 16:00	1.35	1.48	+9.3%	Beat
26 Feb 2026 16:00	1.50	1.57	+5.0%	Beat
06 Nov 2025 16:00	1.43	1.50	+4.7%	Beat
07 Aug 2025 16:00	1.45	1.69	+16.3%	Beat
08 May 2025 16:00	1.22	1.34	+9.7%	Beat
27 Feb 2025 16:00	1.31	1.41	+7.8%	Beat
07 Nov 2024 16:00	1.39	1.64	+17.7%	Beat
08 Aug 2024 16:00	1.51	1.56	+3.7%	Beat
09 May 2024 06:00	1.75	2.08	+19.2%	Beat

Annual results · USD

Year	Revenue	Change	Net income	Net margin	EPS	EPS change	Free cash flow
2025	8.3B	+0.9%	1.6B	18.7%	8.88	+221.7%	-10M
2024	8.3B	+0.7%	479M	5.8%	2.76	-64.6%	805M
2023	8.2B	+0.8%	1.3B	16.4%	7.79	+0.2%	1.6B
2022	8.1B	—	1.3B	16.5%	7.78	—	1.4B

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Day Week Month

Price history in USD, by day
Period	Opening price	High	Low	Closing price	Change	Volume
06 Nov 2026	86.45	93.10	85.04	90.38	+3.67%	3,168,900
05 Nov 2026	90.34	90.50	85.57	87.18	-2.43%	1,880,600
04 Nov 2026	87.49	90.61	87.48	89.35	+5.42%	2,168,000
03 Nov 2026	84.02	85.38	83.71	84.76	+0.01%	1,006,200
02 Nov 2026	82.46	84.76	81.66	84.75	+4.21%	1,242,300
30 Oct 2026	84.15	84.48	80.76	81.33	-2.67%	1,067,200
29 Oct 2026	82.27	83.68	82.25	83.56	+2.09%	1,088,700
28 Oct 2026	83.08	83.33	81.38	81.85	-1.36%	1,564,700
27 Oct 2026	85.36	85.81	82.85	82.98	-3.30%	1,320,000
26 Oct 2026	85.68	87.56	85.68	85.81	+0.47%	975,600
23 Oct 2026	86.92	87.27	84.81	85.41	-2.33%	1,655,500
22 Oct 2026	86.89	87.87	86.42	87.45	+0.90%	769,700
21 Oct 2026	85.74	86.88	85.35	86.67	+0.32%	812,800
20 Oct 2026	86.01	86.72	85.21	86.39	+1.58%	804,500
19 Oct 2026	85.31	86.25	85.04	85.05	-0.89%	851,000
16 Oct 2026	88.42	89.00	85.18	85.81	-2.33%	1,165,400
15 Oct 2026	88.81	89.45	87.25	87.86	+0.69%	1,146,100
14 Oct 2026	86.49	87.45	85.94	87.26	+1.11%	1,031,100
13 Oct 2026	86.01	86.49	83.29	86.30	+1.16%	985,000
12 Oct 2026	87.00	88.26	84.42	85.31	-2.27%	1,454,600
09 Oct 2026	86.66	88.23	86.66	87.29	+1.02%	1,063,900
08 Oct 2026	85.80	86.79	85.25	86.41	+0.62%	1,286,500
07 Oct 2026	85.62	87.25	85.30	85.88	-1.33%	981,100
06 Oct 2026	88.45	88.93	86.89	87.04	-1.12%	914,200
05 Oct 2026	87.52	88.39	86.74	88.03	+0.20%	1,044,000

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

What Is Solventum (SOLV) Signaling With Its 90% Separation And HIS Split Plan? (opens in a new tab) Simply Wall St. · 07 Nov 2026 02:17
SOLV Q3 Earnings Beat Estimates Despite ERP-Related Revenues Decline (opens in a new tab) Zacks · 06 Nov 2026 15:02
Solventum Corp (SOLV) Q3 2026 Earnings Call Highlights: Separation Nears Completion as EPS ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 11:16
Wells Fargo Maintains Equal-Weight on Solventum, Raises Price Target to $95 (opens in a new tab) Benzinga · 06 Nov 2026 10:50
Piper Sandler Reiterates Overweight on Solventum, Raises Price Target to $110 (opens in a new tab) Benzinga · 06 Nov 2026 10:27
Solventum (SOLV) Raises Guidance After Q3 Beat, Is The Stock Still Undervalued? (opens in a new tab) Simply Wall St. · 06 Nov 2026 09:17
Solventum (SOLV) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 06 Nov 2026 07:31
Solventum (NYSE:SOLV) Q3 2026 Earnings: In-Line Revenue, EPS Beat, Shares Flat After Hours (opens in a new tab) ChartMill · 06 Nov 2026 00:44
Solventum (NYSE:SOLV) beats Q3 2026 sales expectations (opens in a new tab) StockStory · 05 Nov 2026 22:47
S&P 500 After-Hours Movers: ABNB and SNDK Gain, AXON and SOLV Fall (opens in a new tab) ChartMill · 05 Nov 2026 22:06
Solventum (SOLV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (opens in a new tab) Zacks · 05 Nov 2026 22:00
Solventum (SOLV) Tops Q3 Earnings Estimates (opens in a new tab) Zacks · 05 Nov 2026 21:45
Solventum: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 05 Nov 2026 21:20
Solventum Reports Third Quarter 2026 Financial Results (opens in a new tab) 05 Nov 2026 21:05
Solventum Corporation (SOLV) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 05 Nov 2026 19:54

Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close: 87.18 USD
Market cap: 15.4B
Exchange: NYSE
Country: United States
Sector: Healthcare
Industry: Medical Instruments & Supplies
Currency: USD

Dividends

No dividends on record.

Why this score

How the score is made up
Part of the score	Points	Why
Business growth Yearly growth of revenue and of earnings per share.	4.4 / 25	Revenue growth of 0.8% a year Earnings per share growth of 4.5% a year
Quality Return on equity, net margin and how stable the margins are.	1.6 / 25	ROE of 3%
Financial strength Net debt against operating earnings, interest cover and free cash flow.	5.3 / 20	Net debt is 4.8× EBITDA Free cash flow yield of 1.2%
Valuation Free cash flow yield and the P/E against its sector.	1.5 / 15	P/E 101.6 against 30.6 for its sector
Analysts How far the analysts' average target is from today's price.	5.9 / 10	Analysts' target is +8% from the price

Heavy debt: net debt is 4.8× EBITDA
Thin interest cover: operating profit is only 1.8× the interest

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.

Figures

Valuation
Figure	Value	Reading	Sector median
P/E (trailing)	101.55×	Weak	30.65×
P/E (forward)	12.15×	Good	14.89×
Price / book	3.2×	Weak	3.81×
Price / sales	1.88×	Good	3.19×
EV / EBITDA	20.12×	Weak	12.63×
Free cash flow yield	1.2%	Weak	2.5%

Quality
Figure	Value	Reading	Sector median
Gross margin	53.8%	Good	58.6%
Operating margin	5.5%	Weak	7.8%
Net margin	1.9%	Weak	2.8%
Return on equity	3.2%	Weak	5.7%
Return on assets	2.1%	Weak	3.6%

Growth
Figure	Value	Reading	Sector median
Revenue growth / year	0.8%	Weak	10.8%
EPS growth / year	4.5%	Fair	9.1%

Financial health
Figure	Value	Reading	Sector median
Debt / equity	1.1×	Fair	0.48×
Net debt / EBITDA	4.83×	Weak	1.6×
Interest cover	1.82×	Weak	2.69×
Current ratio	1.03×	Fair	2.39×

Dividends
Figure	Value	Reading	Sector median
Payout of earnings	0%	Weak	0%

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Follow SOLV and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in